Physician profile
Michael N Mankarious
NPI 1659375921
$3,078.47
in general payments reported to CMS, 2019-2025
29 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $65.08 · 2021: $446 · 2022: $526 · 2023: $499 · 2024: $538 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,386.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $665.20 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $407.70 | 2019-2024 | Repatha, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.04 | 2019-2025 | Stiolto Respimat, Spiriva Respimat, Jardiance |
| Novo Nordisk INC | $180.09 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $142.08 | 2019-2023 | Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $135.90 | 2022-2024 | Austedo Xr |
| Pfizer INC. | $130.37 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $117.99 | 2023-2025 | Ingrezza |
| Glaxosmithkline, LLC. | $108.66 | 2019-2025 | Shingrix |
| Janssen Pharmaceuticals, INC | $100.27 | 2019-2022 | |
| Lilly USA, LLC | $99.65 | 2023-2025 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $98.77 | 2022-2025 | Watchman Flx, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $96.77 | 2019-2023 | |
| Dexcom, INC. | $76.84 | 2023-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $63.65 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $58.76 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $49.29 | 2024-2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $43.86 | 2023-2024 | Rexulti |
| Allergan, INC. | $23.66 | 2020 | |
| Phathom Pharmaceuticals, INC. | $21.74 | 2025 | Voquezna |
| Ucb, INC. | $20.72 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $20.19 | 2023 | Uptravi, Opsumit |
| Eisai INC. | $19.44 | 2021 | |
| Melinta Therapeutics, LLC | $19.43 | 2019 | |
| Merck Sharp & Dohme LLC | $18.16 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.56 | 2022 | |
| Daiichi Sankyo INC. | $17.27 | 2024 | Injectafer |
| Pacira Therapeutics, INC. | $12.28 | 2019 | |
| Mylan Specialty L.P. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mankarious listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.